KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Esperion Therapeutics (ESPR) Short term Debt (2016 - 2018)

Esperion Therapeutics filings provide 2 years of Short term Debt readings, the most recent being $152000.0 for Q2 2018.

On a quarterly basis, Short term Debt changed N/A to $152000.0 in Q2 2018 year-over-year; TTM through Jun 2018 was $152000.0, a N/A change, with the full-year FY2017 number at $1.0 million, changed N/A from a year prior.
Short term Debt hit $152000.0 in Q2 2018 for Esperion Therapeutics, down from $603000.0 in the prior quarter.
In the past five years, Short term Debt ranged from a high of $1.0 million in Q4 2017 to a low of $152000.0 in Q2 2018.